Benzinga | Feb 24, 2021 02:02PM EST

Celcuity Raises $24M Via Upsized Equity Offering At 11% Discount

* Celcuity Inc (NASDAQ: CELC) has priced its upsized underwritten public offering of 1.7 million shares at $14 per share, raising approximately $24 million in gross proceeds. The offer price is at an 11% discount from the last close price of $15.7 on Tuesday.

* Previously the company had announced the offering of $20 million.

* The underwriter has an option to purchase up to an additional 257,100 shares, and the offering will close by February 26.

* Celcuity intends to use the proceeds for working capital and general corporate purposes.

* Craig-Hallum Capital Group is acting as the sole managing underwriter for the offering.

* In January, the company announced a clinical trial collaboration with Sarah Cannon Research Institute and Pfizer Inc to conduct a Phase 2 clinical trial.

* The trial will evaluate the efficacy and safety of two Pfizer targeted therapies VIZIMPRO and XALKORI, in patients with previously treated metastatic HER2-negative breast cancer selected with Celcuity's CELsignia Multi-Pathway Activity Test.

* In December, Celcuity announced a trial collaboration with Massachusetts General Hospital, UCLA, and Vanderbilt and Puma Biotechnology to conduct a Phase 2 trial.

* The company expects to announce additional trial collaborations in the first half of 2021.

* Celcuity ended the fourth quarter with cash and cash equivalents of $11.6 million.

* Price Action: CELC stock is down 7.76% at $14.50 in market trading hours on the last check Wednesday.